Gilead unblinds Phase III study of Zydelig

17 November 2015

US biotech giant Gilead Sciences (Nasdaq: GILD) has announced it is unblinding a Phase III study of Zydelig (idelalisib) following a recommendation by an independent data monitoring committee.

The decision was made after an interim analysis revealed greater progression-free survival and overall survival in patients who took Zydelig in combination with Roche’s (ROG: SIX) Rituxan (rituximab) and Teva’s (NYSE: TEVA) Treanda (bendamustine).

In the study 416 adults, with previously treated chronic lymphocytic leukaemia (CLL) were randomized to six cycles of Rituxan and Treanda over 24 weeks in combination with either Zydelig or a placebo taken twice daily.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK